The 2016 revision of the World Health Organization (WHO) classification of lymphoid neoplasms

Steven H. Swerdlow1*, Elias Campo2*, Stefano A. Pileri3, Nancy Lee Harris4, Harald Stein5, Reiner Siebert6, Ranjana Advani7, Michele Ghiełmini8, Gilles A. Salles9, Andrew D. Zelenetz10, Elaine S. Jaffe11*

1University of Pittsburgh School of Medicine, Pittsburgh, PA; 2Hospital Clinic, University of Barcelona, Barcelona, Spain 3Haematopathology Unit, European Institute of Oncology, Milan; Bologna University Medical School, Bologna, Italy 4Harvard Medical School; Massachusetts General Hospital, Boston, MA 5Pathodiagnostik, Berlin, Germany 6Institute of Human Genetics, Christian-Albrechts-University Kiel, Kiel Germany 7Stanford University, Stanford, CA 8Oncology Institute of Southern Switzerland, Bellinzona, Switzerland 9Hospices Civils de Lyon & Université Claude Bernard Lyon-1, Lyon, France 10Memorial Sloan Kettering Cancer Center and Weill Cornell Medical College, New York, NY 11National Cancer Institute, Bethesda, MD

Short title: 2016 WHO Classification of lymphoid neoplasms

*Corresponding authors:
Steven H. Swerdlow
Director, Division of Hematopathology
Department of Pathology
University of Pittsburgh School of Medicine
200 Lothrop Street
Pittsburgh, PA 15213, USA
Email: swerdlowsh@upmc.edu
Telephone: 412-647-5191
Fax: 412-647-4008

Elias Campo
Department of Pathology
Hospital Clinic, University of Barcelona
Villarroel 170
08036 Barcelona, Spain
Email: ecampo@clinic.ub.es
Telephone: 34 93 227 5450
Fax: 34 93 227 5717

Copyright © 2016 American Society of Hematology
Abstract

A revision of the nearly 8 year old WHO classification of the lymphoid neoplasms and the accompanying monograph is being published. It reflects a consensus among hematopathologists, geneticists and clinicians regarding both updates to current entities as well as the addition of a limited number of new provisional entities. The revision clarifies the diagnosis and management of lesions at the very early stages of lymphomagenesis, refines the diagnostic criteria for some entities, details the expanding genetic/molecular landscape of numerous lymphoid neoplasms and their clinical correlates, and refers to investigations leading to more targeted therapeutic strategies. The major changes are reviewed with an emphasis on the most important advances in our understanding that impact our diagnostic approach, clinical expectations and therapeutic strategies for the lymphoid neoplasms.
Introduction

The 2008 WHO classification of hematopoietic and lymphoid tumors and the associated monograph represent the established guidelines for the diagnosis of malignant lymphomas; however, subsequently there have been major advances with significant clinical and biologic implications. A major revision is therefore being published that will be an update of the current 4th edition and not a truly new 5th edition as there are still other volumes pending in the 4th edition of the WHO tumor monograph series. Because it is considered a part of the 4th edition, while some provisional entities will be promoted to definite entities and a small number of new provisional entities added, there will be no new definite entities.

As with the 2001 and 2008 classifications, an all-important clinical advisory committee meeting was held in 2014 to obtain the advice and consent of clinical hematologists/oncologists and other physicians critical to the revision (see appendix). Additional editorial meetings and consultations followed leading to the updated classification (Table 1). Although there are only limited alterations in the classification compared to 2008, the revised monograph will incorporate a large body of information published over the last 8 years relating to existing entities with some important diagnostic, prognostic and therapeutic implications. The classification maintains the goals of helping to identify homogeneous groups of well-defined entities and facilitating the recognition of uncommon diseases that require further clarification. This manuscript will review the major areas in lymphoid, histiocytic and dendritic neoplasms where changes from the prior edition are foreseen as well as emphasize conceptual themes (Table 2).
**Mature B-cell lymphoid neoplasms**

An important element that pervades many parts of the new monograph derives from an explosion of new clinical, pathological and genetic/molecular data concerning the “small B-cell” lymphomas. The concept that there are lymphoid proliferations that we used to diagnose as overt lymphoid neoplasms but which aren’t considered as such in 2016 will be further emphasized. Among the aggressive B-cell lymphomas, there are major changes that impact how these cases should be evaluated and diagnosed that have important therapeutic implications as well as being of biologic interest.

*Chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL) and monoclonal B-cell lymphocytosis (MBL)*

The 2008 monograph recognized MBL as the presence of monoclonal B-cell populations in the peripheral blood (PB) of up to $5 \times 10^9$/l either with the phenotype of CLL, atypical CLL or non-CLL (CD5-) B-cells in the absence of other lymphomatous features. Found in up to 12% of healthy individuals, in some it may be an extremely small population, but in others associated with a lymphocytosis.³ Whereas in 2008 it was unknown if MBL was a precursor of CLL, we now know that MBL precedes virtually all cases of CLL/SLL.⁴ The updated WHO will retain the current criteria for MBL, but will emphasize that “low count” MBL, defined as a PB CLL count of $<0.5 \times 10^9$/l, must be distinguished from “high count” MBL because low count MBL has significant differences from CLL, an extremely limited, if any, chance of progression and, until new evidence is provided, does not require routine follow-up outside of standard medical care.⁵,⁶ In contrast, high count MBL requires routine/yearly follow-up, and has very similar phenotypic and genetic/molecular features as Rai stage 0 CLL, although IGHV mutated cases are more
frequent in MBL.\textsuperscript{7} Also impacting our diagnostic criteria, the revision will eliminate the option to diagnose CLL with $<5 \times 10^9$/l PB CLL cells in the absence of extramedullary disease even if there are cytopenias or disease-related symptoms. Non-CLL type MBL, at least some of which may be closely related to splenic marginal zone lymphoma, is also recognized.\textsuperscript{8,9}

In addition, while other confirmatory studies are necessary, the concept of tissue-based MBL of CLL type will be discussed as there are a subset of cases with lymph node involvement by “SLL” that also do not seem to have a significant rate of progression. In one retrospective study, lymph nodes with CLL/SLL in which proliferation centers were not observed and patients in whom adenopathy was $<1.5$cm based on CT scans were the best candidates for tissue-based MBL.\textsuperscript{10}

Also related to CLL/SLL, there is increasing interest in proliferation centers (PC) in overt CLL/SLL. We have learned that PC can have cyclin D1 expression in up to about 30\% of CLL/SLL, that they express MYC protein, and, based on 3 of 4 studies, that PC which are large/confluent and/or have a high proliferative fraction are a significant and independent adverse prognostic indicator.\textsuperscript{11-15}

\textit{Follicular lymphoma (FL), in situ follicular neoplasia (ISFN), pediatric-type follicular lymphoma and other related lymphomas}

Consistent with the growing conservatism in lymphoma diagnosis, in situ FL will be renamed \textit{in situ follicular neoplasia} with the criteria remaining those described previously. Much has been learned about these neoplasms, which have a low rate of progression, but are more often
associated with prior or synchronous overt lymphomas, thus requiring additional clinical assessment.\textsuperscript{16,17} They must be distinguished from partial involvement by FL that is more likely to progress.\textsuperscript{16} Unfortunately, the extent of the in situ lesions, such as the number or proportion of abnormal follicles or the degree of involvement within the abnormal follicles, cannot be used to predict which patients have isolated ISFN or who are least likely to progress to an overt lymphoma.\textsuperscript{16,17} ISFN does have fewer chromosomal copy number abnormalities than focal and especially overt FL, although secondary genetic abnormalities are present even in the earliest lesions in addition to $BCL2$ rearrangements.\textsuperscript{18,19} At the very lowest end of this spectrum, cells similar to those with $t(14;18)(q32;q21)$ IGH/$BCL2$ translocation that circulate in many healthy individuals may reside in the germinal centers as non-proliferative centrocytes even in the absence of recognizable ISFN.\textsuperscript{20} However, higher levels of circulating $t(14;18)$-positive lymphocytes ($>10^{-4}$ of total cells) indicate a higher risk for FL.\textsuperscript{21} It is also important to recognize that flow cytometric studies demonstrate populations of B-cells with a FL-type phenotype in about half of all lymph nodes with ISFN.\textsuperscript{17} This is of particular importance in the evaluation of fine needle aspirations in which architectural features cannot be evaluated.

Pediatric FL will become a definite entity in the 2016 classification but now known as \textit{pediatric-type FL} because similar lymphomas may occur in adults.\textsuperscript{22,23} It is a nodal disease characterized by large expansile highly proliferative follicles that often have prominent blastoid follicular center cells rather than classic centroblasts (or centrocytes).\textsuperscript{22} Some have reported a moderate number of cases as grade 1-2 of 3. $BCL2$ rearrangements must not be present, but there may be some $BCL2$ protein expression. They also lack $BCL6$ and $MYC$ rearrangements with ongoing
investigations of their genetic/molecular landscape. Nearly all cases are localized and may not require treatment other than excision. The criteria for pediatric-type FL, however, must be strictly applied to avoid underdiagnosing conventional grade 3 FL, with particular caution required before making this diagnosis in an adult. This category also excludes cases with diffuse areas (i.e. foci of diffuse large B-cell lymphoma, DLBCL). Some studies have raised the possibility that pediatric-type FL might be a “benign clonal proliferation with low malignant potential”. 22, 23

Large B-cell lymphoma with IRF4 rearrangement, which also occurs most commonly in children and young adults, will be considered a distinct new provisional entity (Figure 1 A-D). These lymphomas most typically occur in Waldeyer ring and/or cervical lymph nodes and are low stage. They may have a follicular, follicular and diffuse or pure diffuse growth pattern resembling FL grade 3B or a DLBCL. Strong IRF4/MUM1 expression is seen usually with BCL6 and a high proliferative fraction. BCL2 and CD10 are also expressed in more than half of the cases with a minority CD5 positive. They are most often of germinal center type, particularly based on gene expression profiling studies. Most cases have IG/IRF4 rearrangements sometimes together with BCL6 rearrangements but they uniformly lack BCL2 rearrangements. Some cases that also seem to belong in this category lack a demonstrable IRF4 rearrangement but have strong IRF4/MUM1 expression. This lymphoma is considered to be more aggressive than other pediatric-type FL but patients, at least when treated, have done very well. These cases must be distinguished from the CD10 negative, IRF4/MUM1 positive FL which are often associated with DLBCL and occur in older individuals. 26
The current monograph recognizes GI tract FL as a variant. The revision will emphasize the distinctive nature specifically of duodenal-type FL, which although having features of a localized overt low grade FL, is distinct from other GI tract FL, and has many features that overlap with ISFN as well as some features resembling an extranodal marginal zone lymphoma of mucosa-associated lymphoid tissue (MALT lymphoma). These patients appear to have an excellent outcome, including some cases managed with a watch and wait strategy.

The new monograph will also recognize that while some diffuse-appearing FL may simply reflect a sampling issue, there is a group of distinctive largely diffuse low grade FL that typically present as large localized inguinal masses, lack BCL2 rearrangements and have 1p36 deletions. It should be noted that the latter is not a specific finding and can be seen in other lymphomas including conventional FL.

**Mantle cell lymphoma (MCL), leukemic non-nodal mantle cell lymphoma and in situ mantle cell neoplasia (ISMCN)**

MCL classically has been recognized as an aggressive but incurable small B-cell lymphoma that developed in a linear fashion from naïve B-cells. Two types of clinically indolent variants are now recognized and reflect, in part, that MCL develops along two very different pathways (Figure 2). Classical MCL is usually composed of IGHV unmutated or minimally mutated B-cells that usually express SOX11 and typically involves lymph nodes and other extranodal sites. Acquisition of additional molecular/cytogenetic abnormalities can lead to even more aggressive blastoid or pleomorphic MCL. Other MCL develop from IGHV mutated SOX11 negative B-cells
which leads to **leukemic non-nodal MCL**, usually involving the peripheral blood, bone marrow and often spleen. These cases are frequently clinically indolent; however, secondary abnormalities, often involving TP53 may occur and lead to very aggressive disease. In situ MCL is now to be called **in situ mantle cell neoplasia**, again emphasizing a more conservative approach for lymphoid neoplasms with a low rate of progression. It is characterized by the presence of cyclin D1+ cells, most typically in the inner mantle zones of follicles, in lymphoid tissues that do not otherwise suggest the diagnosis of a MCL, and is often found incidentally, sometimes in association with other lymphomas. They are much less common than ISFN and while they may be disseminated, appear to have a low rate of progression. ISMCN should be distinguished from overt MCL with a mantle zone growth pattern. Nevertheless, these latter cases as well as other classical MCL with a low proliferative fraction may also be relatively indolent.

**Impact of newer molecular/cytogenetic studies related to the small B-cell lymphoid neoplasms**

Next generation sequencing (NGS) studies have led to major advances not only in better understanding the small B-cell lymphoid neoplasms, but to discoveries of diagnostic importance. Whereas the 2008 monograph reported that “No cytogenetic abnormality is specific for [hairy cell leukemia].”, we now know that **BRAF** V600E mutations are found in almost all cases of **hairy cell leukemia** (HCL) but not in HCL-variant or other small B-cell lymphoid neoplasms. More recently mutations in **MAP2K1** which encodes MEK1 (which is downstream of BRAF) have been reported in almost half of HCL-v and in the majority of HCL that use IGHV4-34 and which lack **BRAF** V600E mutations.
Similarly, the 2008 monograph noted “no specific chromosomal or oncogene abnormalities are recognized” in lymphoplasmacytic lymphoma (LPL); however, we now know that about 90% of LPL or Waldenström macroglobulinemia (LPL plus an IgM paraprotein) have MYD88 L265P mutations.\textsuperscript{34} This mutation also is found in a significant proportion of IgM but not IgG or IgA monoclonal gammopathy of undetermined significance cases, a small proportion of other small B-cell lymphomas even after careful review, in approximately 30% of non-germinal center type DLBCL, more than half of primary cutaneous DLBCL, IgM type, and many DLBCL at immune privileged sites but not in plasma cell myeloma, even of IgM type.\textsuperscript{35} Review of cases with and without the mutation have led to revised criteria for LPL, emphasizing the monotony of the lymphoplasmacytic proliferation in cases other than those undergoing transformation, total architectural effacement in some cases, and allowing for significant follicular colonization.\textsuperscript{36} While seeming to be more inclusive, these studies also suggest that cases previously described as polymorphic LPL and some LPL-like cases of gamma heavy chain disease be excluded from the LPL category.\textsuperscript{36,37} These studies also have led to IgM MGUS being thought of as more closely related to LPL or other B-cell lymphomas and segregated from the uniformly wild type MYD88 IgG and IgA MGUS cases that are more closely related to plasma cell myeloma. Consistent with this approach, CXCR4 mutations are found in about 30% of LPL and 20% of IgM MGUS but are not found in IgG or IgA MGUS cases.\textsuperscript{38-40}

The situation with CLL/SLL is quite different and more complex because while there are no recognized disease-defining mutations, there are a large number of mutations that occur with a
relatively low frequency.\textsuperscript{41-50} In addition to their biological implications, at least some such as \textit{TP53}, \textit{NOTCH1}, \textit{SF3B1}, and \textit{BIRC3} are of clinical interest because of their adverse prognostic implications and with some being potential direct or indirect therapeutic targets (Figure 3). It has been suggested that some of these could be integrated into an updated cytogenetic risk profile that also includes the well-known recurrent chromosomal abnormalities typically identified with FISH studies\textsuperscript{49,51}; however, while interest remains in this concept, the literature is inconsistent regarding the clinical implications of some of the mutations and combined risk profile, and it will not be recommended in the revised monograph.\textsuperscript{48,50}

In addition to having many non-random secondary chromosomal gains and losses as well as recurrent copy-neutral loss of heterozygosity that often involves the same regions where the losses occur such as \textit{TP53}, \textbf{MCL} also are characterized by having mutations affecting many different genes with \textit{ATM} (40-75\%) and \textit{CCND1} (35\%) the most frequent.\textsuperscript{52} Other mutations are present in less than 15\% of cases, including some such as \textit{NOTCH1} and \textit{NOTCH2} that are of prognostic and potential therapeutic importance.\textsuperscript{52,53} It has also been learned that about half of \textbf{MCL} that lack cyclin D1 expression/\textit{CCND1} rearrangements have \textit{CCND2} translocations, often with IGK or IGL as a partner locus, a finding that can be of diagnostic utility.\textsuperscript{54}

Much has also been learned about the mutational landscape in terms of the development and progression in \textbf{FL}. Mutations in chromatin regulator/modifier genes, such as \textit{CREBBP} and \textit{KMT2D} (\textit{MLL2}), are extremely common early events and may be potential therapeutic targets.\textsuperscript{55-58} \textit{EZH2} mutations, present in about 20-25\% of \textbf{FL}, are another early event and
potential therapeutic target. Mutations are present in a large number of other genes, including some seen predominantly with transformation, but in significantly lower proportions of patients. A new prognostic model integrating gene mutations with clinical parameters has been proposed, but, while conceptually interesting, requires validation. Whether mutational analysis should be performed routinely for diagnostic, prognostic or therapeutic purposes and if it should be integrated with other pathologic and clinical prognostic factors remains to be determined.

**Diffuse large B-cell lymphoma (DLBCL)**

**Cell of origin classification**

The 2008 classification recognized germinal center B-cell-like (GCB) and activated B-cell-like (ABC) molecular “subgroups” of DLBCL based on gene expression profiling (GEP) as well as a group of cases that could not be put into either category (unclassifiable). The GCB and ABC subgroups differed in their chromosomal alterations, activation of signaling pathways, and clinical outcome. It separately recognized GCB and non-GCB immunohistochemical subgroups based on the Hans algorithm which used antibodies to CD10, BCL6 and IRF4/MUM1 but noted that these groups did not “exactly correlate” with the molecular categories and that these subgroups did not determine therapy. However, because GEP was not available as a routine clinical test, and because there were issues of reproducibility and reliability of immunohistochemical algorithms, subclassification of DLBCL, NOS was considered optional in the 2008 classification. The better understanding of the molecular pathogenesis of these two subgroups since 2008, however, has led to the investigation of more specific therapeutic strategies to mitigate the worse outcome among those with ABC/non-GCB type DLBCL reported
in most studies; prospective trials are ongoing to determine if these therapies should be incorporated into clinical practice. For this reason the revised classification will require the identification of these two subtypes. With GEP still not a routine clinical test, the use of IHC algorithms will be considered acceptable. While the Hans algorithm remains the most popular and has a reasonable correlation with the GEP, other algorithms also may be used. It is acknowledged that the IHC algorithms do not recognize the 10-15% of tumors unclassified by GEP, have reproducibility issues and are not uniformly reported to have prognostic utility. Newer methods based on quantification of RNA transcripts extracted from formalin fixed paraffin embedded tissues provide concordant results with conventional microarray GEP, are reproducible between laboratories, and capture the prognostic impact of the cell of origin classification. These methods are still not accessible to most laboratories but may represent a promising alternative to the current IHC-based algorithms.

Other phenotypic and molecular/cytogenetic features of clinical importance

A significant advance in recent years has been the better understanding of MYC alterations in large B-cell lymphomas (LBCL). MYC is rearranged in 5-15% of DLBCL, NOS and frequently associated with BCL2 or, to a lesser extent BCL6 translocation, in the so-called “double-hit” or “triple-hit” lymphomas that are included in the updated WHO classification in the new category of High grade B-cell lymphoma [HGBL], with rearrangements of MYC and BCL2 and/or BCL6 (see detailed discussion below).

MYC protein expression is detected in a much higher proportion of DLBCL (30-50%) and associated with concomitant expression of BCL2 in 20-35% of cases. Most of these tumors do
not carry MYC/BCL2 chromosomal alterations and have been named “double-expressor (DE) lymphoma”. Most studies use a cut-off of 40% MYC expressing cells to define these cases; the cut off for BCL2 expression has varied considerably in the literature, but a figure of >50% is recommended. In several but not all studies, the DE lymphomas have a worse outcome than other DLBCL, NOS but they are not as aggressive as the HGBL, with rearrangements of MYC and BCL2 and/or BCL6.68,69 These observations have suggested that double expression of MYC and BCL2 proteins without gene aberrations should be considered a prognostic indicator in DLBCL, NOS but not a separate category. CD30 expression in DLBCL, NOS is also of potential interest as it may be a potential target for new antibody-based therapies.

Recent NGS studies have identified common somatic mutations in all subgroups of DLBCL but also a profile of alterations differentially represented in both GCB and ABC subtypes.70 Somatic mutations common in both DLBCL subtypes are inactivating mutations of TP53 and genes involved in immunosurveillance (B2M, CD58), alterations in epigenetic regulators (CREBBP/EP300, KMT2D/C [MLL2/3], MEF2B) and oncogenic activation of BCL6. GCB-DLBCL carry frequent alteration in the histone methyl transferase EZH2, BCL2 translocations, and mutations in the cell motility regulator GNA13, whereas ABC-DLBCL have mutations in genes (MYD88, CD79A, CARD11, TNFAIP3) activating the BCR/TLR and NFKB pathways. Although the clinical implications of these mutations are not fully understood, there are increasing expectations that they will become important in guiding future targeted therapies.61,71

Epstein-Barr virus positive (EBV+) large B-cell lymphomas and EBV+ mucocutaneous ulcer (MCU)
The 2008 monograph included the “EBV-positive DLBCL of the elderly” as a provisional entity. These tumors occur in apparently immunocompetent patients usually >50 years old and have a worse prognosis than EBV-negative tumors. EBV-positive DLBCL, however, have been increasingly recognized in younger patients, with a broader morphological spectrum and better survival than initially thought. This new information has led to substitute the modifier “elderly” with “not otherwise specified” (EBV+ DLBCL, NOS) in the updated classification. The NOS is to highlight that there are other more specific entities with neoplastic EBV+ large B-cells, such as lymphomatoid granulomatosis. In addition, the new category “EBV+ mucocutaneous ulcer” has been segregated from the EBV+ DLBCL as a provisional entity due to its self-limited growth potential and response to conservative management. These lesions may present in advanced age or with iatrogenic immunosuppression.

Burkitt lymphoma

Recent NGS studies of Burkitt lymphoma (BL) have improved our understanding of the pathogenesis of these tumors. Mutations in the transcription factor TCF3 or its negative regulator ID3 occur in about 70% of sporadic and immunodeficiency related BL and 40% of endemic cases. TCF3 promotes survival and proliferation in lymphoid cells by activating the BCR/PI3K signaling pathways and modulating the expression of cyclin D3, which is also mutated in 30% of BL.

One controversial issue not fully resolved is whether true BL without MYC translocations really exist. Some recent studies have identified a subset of lymphomas that resemble BL morphologically, to a large extent phenotypically and by GEP, but which lack MYC
rearrangements. Instead they have a chromosome 11q alteration characterized by proximal gains and telomeric losses.\textsuperscript{81,82} Compared to BL, these lymphomas have more complex karyotypes, lower levels of MYC expression, a certain degree of cytological pleomorphism, occasionally a follicular pattern, and frequently a nodal presentation. The clinical course seems to be similar to BL, but the number of cases reported is still limited. Although more studies are needed, the consensus for the revised WHO classification was to consider these a new provisional entity designated “\textit{Burkitt-like lymphoma with 11q aberration}” (Figure 3E-H).

\textbf{High grade B-cell lymphomas (HGBL), with and without MYC and BCL2 or BCL6 translocations}

The 2008 WHO classification introduced the category of “B-cell lymphoma, unclassifiable, with features intermediate between DLBCL and BL” (BCLU) to recognize a subset of very aggressive tumors in which the distinction between DLBCL and BL was very difficult. Lymphomas with a GEP intermediate between that of molecular BL and molecular non-BL (mostly DLBCL), also lends support to the existence of these intermediate-type cases, which were not, however, considered a specific entity.\textsuperscript{83,84} Segregation of these cases was also necessary to better define these clinically problematic tumors.\textsuperscript{2} Additional studies followed that demonstrated that BCLU and other LBCL, with rearrangements of \textit{MYC} and \textit{BCL2} and/or \textit{BCL6} had mutational features intermediate between DLBCL and BL. They also better characterized the double/triple hit lymphomas, including identifying features that might mitigate the adverse clinical impact of \textit{MYC} translocations.\textsuperscript{67,85-87} The criteria for BCLU, however, are vague and the diagnosis has not been used uniformly, limiting its utility as a diagnostic category.\textsuperscript{67,85,86}

\textbf{All LBCL with \textit{MYC} and \textit{BCL2} and/or \textit{BCL6} rearrangements will be included in a single category to be designated \textit{HGBL, with MYC and BCL2 and/or BCL6 rearrangements}, except for cases that}
fulfill the criteria for a follicular or lymphoblastic lymphoma (Figures 4 and 5). The morphologic appearance should be noted in a comment. The category of BCLU will be eliminated. Cases that appear blastoid or cases intermediate between DLBCL and BL but which lack a MYC and BCL2 and/or BCL6 rearrangement, will be placed in the category of HGBL, NOS. A consensus has not yet been reached to provide specific guidelines as to which LBCL should have FISH studies. Some believe that all DLBCL should have genetic studies for the detection of MYC, BCL2 and BCL6 rearrangements, while others would limit them, for example, to cases with a GCB phenotype and/or high grade morphology or to cases with >40% MYC+ cells.

Mature T and NK-cell neoplasms

**Nodal T-cell lymphomas: Angioimmunoblastic T-cell lymphoma (AITL), Follicular T-cell lymphoma (FTCL), and Peripheral T-cell lymphoma, not otherwise specified (PTCL, NOS)**

Significant advances have occurred in the classification of both nodal and extranodal T-cell and NK-cell neoplasms, which have led to revisions in the classification and introduction of new provisional entities. Many of these changes are the result of genomic studies using approaches to examine GEP and the genetic landscape of T-cell and NK-cell neoplasms.

There have been new insights into the complexity of nodal PTCL. Genetic studies have shown recurrent mutations that affect a significant proportion of cases of AITL. Importantly, many of the same genetic changes are observed in cases of PTCL, NOS that manifest a T follicular helper (TFH) phenotype.\(^{88-90}\) For this designation, the neoplastic cells should express at least two or three TFH-related antigens, including CD279/PD1, CD10, BCL6, CXCL13, ICOS, SAP, and CCR5. This common phenotype has led to FTCL and AITL being unified under a common heading. Cases of nodal PTCL with TFH phenotype will be included here as well. Recurrent genetic
abnormalities include TET2, IDH2, DNMT3A, RHOA, and CD28 mutations, as well as gene fusions such as ITK-SYK or CTLA4-CD28. All these lesions can take part in the process of lymphomagenesis and may represent the target of tailored therapies (e.g. epigenetic modifiers). These cases also share many features by gene expression profiling (GEP).

Both AITL and FTCL may contain B-cell blasts, often EBV-positive, in addition to the neoplastic TFH cells. In some cases the atypical B-cell blasts simulate Hodgkin-Reed Sternberg (HRS) cells, leading to a mistaken diagnosis of classical Hodgkin lymphoma (CHL).\textsuperscript{91,92} Progression to EBV-positive, and more rarely EBV-negative, B-cell neoplasms may occur in a subset of cases.\textsuperscript{93} Nevertheless, although the neoplastic cells share a TFH phenotype and share many genetic changes, clinical and pathological differences remain, so that both diagnoses are retained in the classification. FTCL more often presents with localized disease, with fewer systemic symptoms.

The cases remaining in the PTCL, NOS category still show extreme cytological and phenotypic heterogeneity. Gene expression profiling (GEP) studies display a global signature close to the one of activated T-lymphocytes. GEP analysis of 372 cryopreserved PTCLs identified at least three subtypes characterized by overexpression of GATA3, TBX21, and cytotoxic genes, as well as expression of the corresponding molecules using immunohistochemistry (IHC).\textsuperscript{94} These subtypes are associated with a different clinical behavior and response to therapy. The GATA3 subtype has an inferior prognosis, shows high levels of Th2 cytokines, and can be identified by IHC.\textsuperscript{95} Studies employing NGS are at an early stage in PTCL, NOS, but have provided new insights, which may lead to further refinement in the classification or new targets for therapy. These studies have identified mutations of epigenetic mediators (KMT2D [MLL2], TET2, KDM6A, ARID1B, DNMT3A, CREBBP, MLL, and ARID2), genes involved in signaling pathways (TNFAIP3,
APC, CHD8, ZAP70, NF1, TNFRSF14, TRAF3), and tumor suppressors (TP53, FOXO1, BCORL1, ATM).⁹⁶

Anaplastic Large Cell Lymphomas: ALK-positive, ALK-negative, and Breast Implant Associated

GEP studies also have provided insights into the distinction of CD30-expressing T-cell lymphomas, and have facilitated the distinction of PTCL with high CD30 expression from ALK-negative ALCL, the latter having a superior prognosis.⁹⁷,⁹⁸ ALK-positive and ALK-negative anaplastic large cell lymphoma (ALCL) were both recognized in the 2008 classification, although ALK-negative ALCL was considered a provisional entity, as criteria for distinguishing ALK-negative ALCL from CD30+ PTCL were imperfect. Improved criteria now exist for the recognition of ALK-negative ALCL in daily practice, and it is no longer considered provisional.⁹⁹

GEP studies have shown that ALK-negative ALCL has a signature quite close to that of ALK-positive ALCL and distinct from other NK/T-cell lymphomas. More recent studies illuminating the genetic landscape of ALK-negative ALCL have shown convergent mutations and kinase fusions that lead to constitutive activation of the JAK/STAT3 pathway.¹⁰⁰ These studies provide a genetic rationale for the morphologic and phenotypic similarities between ALK-positive and negative ALCL. However, not all cases of ALK-negative ALCLs are created equal. A subset with rearrangements at the locus containing DUSP22 and IRF4 in chromosome 6p25 tend to be relatively monomorphic, usually lack cytotoxic granules and have been reported to have a superior prognosis, whereas a small subset with TP63 rearrangements are very aggressive (Figure 6A).¹⁰¹,¹⁰²,¹⁰³ Interestingly, the same locus in 6p25 has also been implicated in lymphomatoid papulosis (LYP) and primary cutaneous ALCL.¹⁰⁴,¹⁰⁵ LYP is a clinically diverse disorder, and in recent years a number of new pathological and clinical variants have been
described. The WHO classification recognizes the original variants, types A, B, and C; as well as the more recently described types D (mimics primary cutaneous aggressive epidermotropic CD8+ cytotoxic T-cell lymphoma), E (angioinvasive), and LyP with chromosome 6p25 rearrangement, as well as some even more rare variants. Appreciation of these variants is important, as histologically they can mimic very aggressive T-cell lymphomas, but they are clinically similar to other forms of LYP.

A number of studies in recent years have identified a unique form of ALK-negative ALCL arising in association with breast implants (Figure 6B). First described in 1997, it usually presents as an accumulation of seroma fluid between the implant itself and the surrounding fibrous capsule. Both saline and silicone filled implants have been implicated, with a median interval from the time of the implant to the lymphoma of about 10 years. In most cases the neoplastic cells are confined to the seroma fluid, without invasion of the capsule. In such cases conservative management is recommended, with removal of the implant and capsule. If there is invasion through the capsule, there is risk of lymph node involvement and systemic spread, warranting systemic chemotherapy. The factors leading to progression have not been delineated.

Cytotoxic T-cell Lymphomas and Leukemias

Mature T-cell and NK-cell lymphomas and leukemias expressing cytotoxic molecules constitute a heterogeneous group of diseases with variations in clinical behavior and prognosis. Other than ALCL, most of these neoplasms present with extranodal disease, or are systemic with
involvement of liver, spleen and bone marrow. Since the publication of the 2008 monograph, several entities have received greater recognition, and the revised classification reflects the new data. Besides breast implant associated ALCL, we have the addition of *indolent T-cell lymphoproliferative disorder (LPD) of the GI tract* and *primary cutaneous acral CD8+ T-cell lymphoma* as provisional entities.\textsuperscript{114,115} Both are clonal disorders, usually composed of CD8-positive T cells, with an indolent clinical course. The cutaneous acral lesions, first recognized affecting the ear, are nearly always localized to a single site and can be managed conservatively (Figure 6 C-D). Indolent T-cell LPD of the GI tract can be derived from either CD8 or less often CD4-positive T cells, affects many sites in the GI tract, but has an indolent clinical course. Their optimal management is not yet determined.

The desire to categorize lymphomas according to the precise cellular origin is attractive, but among the mature T-cell lymphomas, promiscuity is observed. Some years ago it was recognized that while hepatosplenic T-cell lymphoma (HSTCL) is usually of \( \gamma \delta \) T-cell derivation, some cases have an \( \alpha \beta \) phenotype,\textsuperscript{116} yet are otherwise clinically and genetically similar. Furthermore, among cutaneous T-cell lymphomas, while \( \gamma \delta \) TCL are generally aggressive,\textsuperscript{117,118} \( \gamma \delta \) variants of mycosis fungoides or other TCLs with an indolent clinical course have been described.\textsuperscript{119,120}

Recent studies have identified recurrent mutations affecting the JAK/STAT pathway in many T-cell and NK-cell malignancies, further emphasizing the overlapping biology in many of these malignancies.\textsuperscript{121-124} *STAT3* mutations are common in *large granular lymphocyte (LGL)*
leukemias of both T-cell and NK-cell types.\textsuperscript{121,122} \textit{STAT5B} mutations are more uncommon and are associated with more clinically aggressive disease.\textsuperscript{125} Recurrent mutations of \textit{STAT5B} and less often \textit{STAT3} are seen in HSTCL of γδ origin\textsuperscript{126} and a similar pattern was observed in primary cutaneous TCL.\textsuperscript{127} Additionally, \textit{STAT5B} mutations were reported in 36\% of cases of what has been known as enteropathy-associated T-cell lymphoma (EATL), type II, all of which were of γδ T-cell origin.\textsuperscript{127}

These data and others have led to changes in the categorization of intestinal T-cell lymphomas. It has become apparent that the two subtypes of EATL are distinct, and will be more clearly distinguished in the revised WHO classification.\textsuperscript{128} EATL, Type I, now simply designated as enteropathy-associated T-cell lymphoma, is closely linked to celiac disease, and is primarily a disease of individuals of northern European origin. EATL, type II, now formally designated as monomorphic epitheliotropic intestinal T-cell lymphoma (MEITL), shows no association with celiac disease, and appears increased in incidence in Asians, and Hispanic populations (Figure 6 E-F). While EATL generally has a polymorphic cellular composition and wide range in cytology, MEITL is monomorphic, and usually positive for CD8, CD56, and MAPK.\textsuperscript{129} Gains in chromosome 8q24 involving \textit{MYC} are seen in a high proportion of cases.\textsuperscript{130} Many cases of MEITL are derived from γδ T-cells, but exceptions exist; some cases are TCR silent and some cases express TCR αβ.\textsuperscript{131} Likewise, most cases of EATL express TCR αβ, but γδ variants exist. As noted above, mutations in \textit{STAT5B} were only associated with γδ MEITL, but investigation of classical EATL or αβ cases was limited.

\textbf{Cutaneous T-cell lymphomas}
Primary cutaneous acral CD8+ TCL and primary cutaneous γδ TCL are discussed above. Primary cutaneous CD4+ small medium TCL was included as a provisional entity in the 2008 classification (Figure 6 G-H). Since then several clinical series have been reported, further elucidating its cellular origin and clinical behavior. The cells have a TFH phenotype, but recurrent mutations as seen in nodal TFH lymphoma have not been reported. The clinical behavior is almost always indolent, with most patients presenting with localized disease. Systemic disease is rare, and conservative local management is sufficient in most patients. It has been suggested that this may represent a limited clonal response to an unknown stimulus, not fulfilling criteria for malignancy. The terminology in the revised classification has been modified to reflect this uncertain malignant potential, designating these cases as primary cutaneous CD4 positive small/medium T-cell lymphoproliferative disorder.

**EBV-positive T-cell and NK-cell lymphomas**

The most common EBV-positive NK-cell or T-cell lymphoma is extranodal NK/T-cell lymphoma, nasal type, which usually presents in the upper aerodigestive tract. However, there are less common EBV-positive T-cell lymphomas and leukemias with different clinical presentations and biology. These are delineated in the upcoming revision of the WHO classification, and somewhat modified from the 2008 monograph. EBV-associated T- and NK-cell lymphoproliferative disorders in the pediatric age group include two major groups: chronic active EBV-infection (CAEBV), and systemic EBV-positive T-cell lymphoma of childhood. Both occur with increased frequency in Asians, and in indigenous populations from Central and South America and Mexico. CAEBV of T/NK type shows a broad range of clinical manifestations.
from indolent, localized forms like hydroa vacciniforme-like lymphoproliferative disorder and severe mosquito bite allergy to a more systemic form characterized by fever, hepatosplenomegaly and lymphadenopathy with or without cutaneous manifestations. Systemic EBV+ T-cell lymphoma of childhood -- no longer referred to as a “lymphoproliferative disorder” -- has a fulminant clinical course usually associated with a hemophagocytic syndrome. The differential diagnosis includes acute EBV-associated hemophagocytic lymphohistiocytosis (HLH), which can present acutely, but in some patients responds well to the HLH 94 protocol, and is not considered neoplastic. Node-based EBV-positive PTCL, defined as demonstrating EBV in the majority of the neoplastic cells, are uncommon and included under the broad heading of PTCL, NOS. They are generally monomorphic and lack the angioinvasion and necrosis of extranodal NK/T-cell lymphoma. They most often present in older adults, and also can be seen in the post-transplant setting and other immunodeficiency states.

**Hodgkin lymphomas**

Although the classification of Hodgkin lymphomas (HL) has not changed, the revision will include updates concerning nodular lymphocyte predominant HL (NLPHL). It has long been recognized that NLPHL can have varied growth patterns, including some with diffuse areas and/or numerous T-cells. Additionally, cases manifesting one of the variant patterns have been reported to be associated with advanced disease and a higher relapse rate, although they still have good survivals. Thus, it is useful to note these features in the diagnostic report. NLPHL may evolve to a completely diffuse T-cell rich proliferation lacking any follicular dendritic cells which would be consistent with a T-cell histiocyte rich large B-cell lymphoma (THRLBCL) or
can be associated with such a proliferation at a separate site. Whereas the 2008 monograph said “It is probably good practice to label cases of NLPHL that progress to a diffuse T-cell-rich pattern as NLPHL, THRLBCL-like…” the revision will recommend the designation of THRLBCL-like transformation of NLPHL, with inclusion of the word “like” due to some remaining uncertainties. This consensus was based on the conclusion from the Clinical Advisory Committee that transformation of NLPHL to DLBCL should be based on WHO criteria (with THRLBCL being a type of large B-cell lymphoma). Recent data indicate that progression to a process with features of THRLBCL is associated with a more aggressive clinical course, and requires different management, such that the term NLPHL in this setting may not be sufficient. However, cases with only focal diffuse areas are not considered transformation. It is also of interest that aside from their immunomorphologic appearance, GEP and array comparative genomic hybridization studies have shown similarities between NLPHL and THRLBCL suggesting a relationship to each other, in spite of other major differences. The revision will also acknowledge that lymphocyte rich classical HL has some features that are intermediate between other classical HL and NLPHL.

Histiocytic and dendritic cell neoplasms (HDCN)

The classification of the HDCN is similar to that from 2008 except that the order of the entities is minimally altered and Erdheim-Chester disease (ECD) has been added, as it should be distinguished from other members of the juvenile xanthogranuloma (JXG) family. HDCN are grouped together based on the functional properties of their normal counterpart (i.e. phagocytosis and/or processing and presentation of antigens) rather than their cell of origin.
While most arise from a common myeloid precursor, a few are of mesenchymal origin (i.e., follicular dendritic cell sarcoma (FDCS) and fibroblastic reticular cell tumor).

During the last few years, several publications highlighted that, irrespective of their myeloid or mesenchymal origin, some of these neoplasms are associated with or preceded by FL, CLL, B- or T-lymphoblastic neoplasms, or PTCL. These cases carry the same TCR or IGHV rearrangements and chromosomal aberrations as the associated lymphoid neoplasms, suggesting a process of transdifferentiation. Moreover, the BRAF V600E mutation has been reported in the setting of Langerhans cell histiocytosis, histiocytic sarcoma, disseminated JXG, ECD, and even FDCS.

Summary
There have been major advances in our knowledge of the lymphoid neoplasms and how they should best be treated over the last 8 years. We have seen new insights into the biology and management of both clonal proliferations with limited malignant potential, as well as the aggressive lymphoid neoplasms where more targeted and effective therapies are being investigated. The 2016 WHO classification and associated monograph aim to provide updated diagnostic categories and criteria, together with biological and clinical correlates, and to facilitate state-of-the-art patient care, future therapeutic advances and basic research in this field.
Acknowledgements

SAP was supported in part through the Italian Association for Cancer Research (AIRC, Milan) Grant 5x1000 number 10007. ADZ was supported in part through the NIH/NCI Cancer Center Support Grant P30 CA008748. The authors wish to acknowledge the unrestricted financial support of the Clinical Advisory Committee meeting held in Chicago, March 31-April 1, 2014 from the following organizations: American Society of Hematology, Josep Carreras Foundation, Fondazione Italiana Linfomi (FIL), Leukemia Clinical Research Foundation, University of Chicago Comprehensive Cancer Center, Beckman/Coulter Corporation, Celgene Corporation, Dako, Genentech Corporation, Incyte Corporation, Leica Corporation, Millennium Pharmaceuticals, Pharmacyclics, Seattle Genetics Corporation, Sysmex Corporation and Ventana Medical Systems, Inc., a member of the Roche Group. The Clinical Advisory Committee meeting would also not have been possible without the major support from James W. Vardiman, lead organizer, and the staff at the University of Chicago.

Author contributions

All authors contributed to the contents of this manuscript which was written by SHS, EC, SAP and ESJ and reviewed and edited by all authors.

Conflict of interest disclosures
SHS, EC, NLH, HS, RS, ESJ, RA, GS, ADZ have nothing to disclose. SAP is member of the Scientific Advisory Board of Takeda/Millennium. MG has received honoraria from Roche, Cellgene, Janssen, Gilead, Millenium, and Mundipharma.

References


17. Pillai RK, Surti U, Swerdlow SH. Follicular lymphoma-like B-cells of uncertain significance (in situ follicular lymphoma) may infrequently progress, but precedes follicular lymphoma, is associated with other overt lymphomas and mimics follicular lymphoma in flow cytometric studies. *Haematologica*. 2013.


60. Young RM, Shaffer AL, 3rd, Phelan JD, Staudt LM. B-cell receptor signaling in diffuse large B-cell lymphoma. *Semin Hematol* (ed 2015/03/26); 2015:77-85.


Table 1. 2016 WHO classification of mature lymphoid, histiocytic and dendritic neoplasms

MATURE B-CELL NEOPLASMS
Chronic lymphocytic leukemia / small lymphocytic lymphoma
Monoclonal B-cell lymphocytosis*
B-cell prolymphocytic leukemia
Splenic marginal zone lymphoma
Hairy cell leukemia
Splenic B-cell lymphoma/leukemia, unclassifiable
  - Splenic diffuse red pulp small B-cell lymphoma
  - Hairy cell leukemia-variant
Lymphoplasmacytic lymphoma
  - Waldenström macroglobulinemia
Monoclonal gammopathy of undetermined significance (MGUS), IgM*
Mu heavy chain disease
Gamma heavy chain disease
Alpha heavy chain disease
Monoclonal gammopathy of undetermined significance (MGUS), IgG/A*
Plasma cell myeloma
Solitary plasmacytoma of bone
Extraosseous plasmacytoma
Monoclonal immunoglobulin deposition diseases*
Extranodal marginal zone lymphoma of mucosa-associated lymphoid tissue (MALT lymphoma)
Nodal marginal zone lymphoma
  - Pediatric nodal marginal zone lymphoma
Follicular lymphoma
  - In situ follicular neoplasia*
  - Duodenal-type follicular lymphoma*
Pediatric-type follicular lymphoma*
Large B-cell lymphoma with IRF4 rearrangement*
Primary cutaneous follicle center lymphoma
Mantle cell lymphoma
  - In situ mantle cell neoplasia*
Diffuse large B-cell lymphoma (DLBCL), NOS
  - Germinal center B-cell type*
  - Activated B-cell type*
T cell/histiocyte-rich large B-cell lymphoma
Primary DLBCL of the CNS
Primary cutaneous DLBCL, leg type
EBV positive DLBCL, NOS*
EBV+ Mucocutaneous ulcer*
DLBCL associated with chronic inflammation
Lymphomatoid granulomatosis
Primary mediastinal (thymic) large B-cell lymphoma
Intravascular large B-cell lymphoma
ALK positive large B-cell lymphoma
Plasmablastic lymphoma
Primary effusion lymphoma
**HHV8 positive DLBCL, NOS**
Burkitt lymphoma
*Burkitt-like lymphoma with 11q aberration*
High grade B-cell lymphoma, with MYC and BCL2 and/or BCL6 rearrangements
High grade B-cell lymphoma, NOS
B-cell lymphoma, undiagnosable, with features intermediate between DLBCL and classical Hodgkin lymphoma

**MATURE T-AND NK-NEOPLASMS**
T-cell prolymphocytic leukemia
T-cell large granular lymphocytic leukemia
**Chronic lymphoproliferative disorder of NK cells**
Aggressive NK cell leukemia
Systemic EBV+ T-cell Lymphoma of childhood
Hydroa vacciniforme-like lymphoproliferative disorder
Adult T-cell leukemia/lymphoma
Extranodal NK/T-cell lymphoma, nasal type
Enteropathy-associated T-cell lymphoma
Monomorphic epitheliotropic intestinal T-cell lymphoma
*Indolent T-cell lymphoproliferative disorder of the GI tract*
Hepatosplenic T-cell lymphoma
Subcutaneous panniculitis-like T-cell lymphoma
Mycosis fungoides
Sézary syndrome
Primary cutaneous CD30 positive T-cell lymphoproliferative disorders
  Lymphomatoid papulosis
  Primary cutaneous anaplastic large cell lymphoma
Primary cutaneous gamma-delta T-cell lymphoma
Primary cutaneous CD8 positive aggressive epidermotropic cytotoxic T-cell lymphoma
Primary cutaneous acral CD8+ T-cell lymphoma
Primary cutaneous CD4 positive small/medium T-cell lymphoproliferative disorder
Peripheral T-cell lymphoma, NOS
Angioimmunoblastic T-cell lymphoma
*Follicular T-cell lymphoma*
*Nodal peripheral T-cell lymphoma with TFH phenotype*
Anaplastic large cell lymphoma, ALK positive
Anaplastic large cell lymphoma, ALK negative
*Breast implant-associated anaplastic large cell lymphoma*

**HODGKIN LYMPHOMA**
Nodular lymphocyte predominant Hodgkin lymphoma
Classical Hodgkin lymphoma
  Nodular sclerosis classical Hodgkin lymphoma
  Lymphocyte-rich classical Hodgkin lymphoma
  Mixed cellularity classical Hodgkin lymphoma
  Lymphocyte-depleted classical Hodgkin lymphoma

POST-TRANSPLANT LYMPHOPROLIFERATIVE DISORDERS (PTLD)
Plasmacytic hyperplasia PTLD
Infectious mononucleosis PTLD
Florid follicular hyperplasia PTLD*
Polymorphic PTLD
Monomorphic PTLD (B- and T/NK-cell types)
Classical Hodgkin lymphoma PTLD

HISTIOCYTIC AND DENDRITIC CELL NEOPLASMS
Histiocytic sarcoma
Langerhans cell histiocytosis
Langerhans cell sarcoma
Indeterminate dendritic cell tumour
Interdigitating dendritic cell sarcoma
Follicular dendritic cell sarcoma
Fibroblastic reticular cell tumour
Disseminated juvenile xanthogranuloma
Erdheim/Chester disease*

1Changes from the 2008 classification are marked with an asterisk. Provisional entities are listed in italics.

Table 2. Highlights of changes in 2016 WHO classification of lymphoid, histiocytic and dendritic neoplasms

<table>
<thead>
<tr>
<th>Entity/category</th>
<th>Change</th>
</tr>
</thead>
</table>
| CLL/SLL         | • Cytopenias or disease-related symptoms are now insufficient to make a diagnosis of CLL with <5x10^9/l PB CLL cells.  
|                 | • Large/confluent and/or highly proliferative proliferation centers are adverse prognostic indicators.  
<p>|                 | • Mutations of potential clinical |</p>
<table>
<thead>
<tr>
<th>Condition</th>
<th>Key Points</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Monoclonal B-cell lymphocytosis</strong></td>
<td>• Must distinguish low count from high count MBL.</td>
</tr>
<tr>
<td></td>
<td>• A lymph node equivalent of MBL exists.</td>
</tr>
<tr>
<td><strong>Hairy cell leukemia</strong></td>
<td>• <em>BRAF</em> V600E mutations in vast majority of cases with <em>MAP2K1</em> mutations in most cases that use <em>IGHV4-34</em> and lack <em>BRAF</em> mutation.</td>
</tr>
<tr>
<td><strong>Lymphoplasmacytic lymphoma (LPL)</strong></td>
<td>• <em>MYD88</em> L265P mutation in vast majority of cases impacting diagnostic criteria even though finding is not specific for LPL.</td>
</tr>
<tr>
<td></td>
<td>• IgM MGUS is more closely related to LPL and other B-cell lymphomas than to myeloma.</td>
</tr>
<tr>
<td><strong>Follicular lymphoma (FL)</strong></td>
<td>• Mutational landscape better understood but clinical impact remains to be determined.</td>
</tr>
<tr>
<td><strong>In situ follicular neoplasia</strong></td>
<td>• New name for in situ follicular lymphoma reflects low risk of progression to lymphoma.</td>
</tr>
<tr>
<td><strong>Pediatric-type FL</strong></td>
<td>• A localized clonal proliferation with excellent prognosis; conservative therapeutic approach may be sufficient.</td>
</tr>
<tr>
<td></td>
<td>• Occurs in children and young adults, rarely in older individuals.</td>
</tr>
<tr>
<td><strong>Large B-cell lymphoma with <em>IRF4</em> rearrangement</strong></td>
<td>• New provisional entity to distinguish from pediatric-type FL and other DLBCL</td>
</tr>
<tr>
<td></td>
<td>• Localized disease, often involves cervical lymph nodes or Waldeyer ring.</td>
</tr>
<tr>
<td><strong>Duodenal-type FL</strong></td>
<td>• Localized lymphoma with low risk for dissemination.</td>
</tr>
<tr>
<td><strong>Predominantly diffuse FL with 1p36 deletion</strong></td>
<td>• Accounts for some cases of diffuse FL, lacks <em>BCL2</em> rearrangement; presents as localized mass, often inguinal</td>
</tr>
<tr>
<td><strong>Mantle cell lymphoma (MCL)</strong></td>
<td>• Two MCL subtypes recognized with different clinicopathological manifestations and molecular pathogenetic pathways – one largely with unmutated/minimally mutated</td>
</tr>
<tr>
<td>In situ mantle cell neoplasia</td>
<td>• New name for in situ MCL, reflecting low clinical risk.</td>
</tr>
<tr>
<td>-------------------------------</td>
<td>----------------------------------------------------------</td>
</tr>
</tbody>
</table>
| Diffuse large B-cell lymphoma, NOS | • Distinction of GCB versus ABC/non-GC type required with use of immunohistochemical algorithm acceptable, may affect therapy.  
• Co-expression of MYC and BCL2 considered new prognostic marker (double expressor lymphoma)  
• Mutational landscape better understood but clinical impact remains to be determined. |
| EBV+ DLBCL, NOS | • This term replaces EBV-positive DLBCL of the elderly since it may occur in younger patients.  
• Does not include EBV+ B-cell lymphomas that can be given a more specific diagnosis. |
| EBV+ mucocutaneous ulcer | • Newly recognized entity associated with iatrogenic immunosuppression or age-related immunosenescence. |
| Burkitt lymphoma | • TCF3 or ID3 mutations in up to approximately 70% of cases. |
| Burkitt-like lymphoma with 11q aberration | • New provisional entity that closely resembles Burkitt lymphoma but lacks MYC rearrangement and has some other distinctive features. |
| High grade B-cell lymphoma, with MYC and BCL2 and/or BCL6 translocations | • New category for all ‘double/triple hit’ lymphomas other than FL or lymphoblastic lymphomas. |
| **High grade B-cell lymphoma, NOS** | - Together with the new category for the ‘double/triple hit’ lymphomas, replaces the 2008 category of B-cell lymphoma, undifferentiable, with features intermediate between DLBCL and Burkitt lymphoma (BCLU).
- Includes blastoid-appearing large B-cell lymphomas and cases lacking MYC and BCL2 or BCL6 translocations that would formerly have been called BCLU. |
|-----------------------------------|---------------------------------------------------------------------------------------------------------------|
| **T-cell large granular lymphocyte leukemia** | - New subtypes recognized with clinicopathologic associations.
- STAT3 and STAT5B mutations in a subset, latter associated with more clinically aggressive disease. |
<table>
<thead>
<tr>
<th></th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Systemic EBV+ T-cell Lymphoma of childhood</strong></td>
<td>- Name changed from lymphoproliferative disorder to lymphoma due to its fulminant clinical course and desire to clearly distinguish it from chronic active EBV infection.</td>
</tr>
<tr>
<td>-------------------------------</td>
<td>-------------------------------------------------------------------------------------------------------------------</td>
</tr>
<tr>
<td><strong>Hydroa vacciniforme-like lymphoproliferative disorder</strong></td>
<td>- Name changed from lymphoma to lymphoproliferative disorder due to its relationship with chronic active EBV infection and a spectrum in terms of its clinical course</td>
</tr>
<tr>
<td>-----------------------------</td>
<td>-------------------------------------------------------------------------------------------------------------------</td>
</tr>
<tr>
<td><strong>Enteropathy associated T-cell lymphoma (EATL)</strong></td>
<td>- Diagnosis only to be used for cases formerly known as type I EATL, typically associated with celiac disease.</td>
</tr>
<tr>
<td>-----------------------------</td>
<td>-------------------------------------------------------------------------------------------------------------------</td>
</tr>
<tr>
<td><strong>Monomorphic epitheliotrophic intestinal T-cell lymphoma</strong></td>
<td>- Formerly type II EATL; segregated from type I EATL and given a new name due to its distinctive nature and lack of association with celiac disease.</td>
</tr>
<tr>
<td>-----------------------------</td>
<td>-------------------------------------------------------------------------------------------------------------------</td>
</tr>
<tr>
<td><strong>Indolent T-cell lymphoproliferative disorder of the GI tract</strong></td>
<td>- New indolent provisional entity with superficial monoclonal intestinal T-cell infiltrate, some cases show progression.</td>
</tr>
<tr>
<td>-----------------------------</td>
<td>-------------------------------------------------------------------------------------------------------------------</td>
</tr>
<tr>
<td><strong>Lymphomatoid papulosis</strong></td>
<td>- New subtypes described with similar clinical behavior but atypical histologic/immunophenotypic features.</td>
</tr>
<tr>
<td>-----------------------------</td>
<td>-------------------------------------------------------------------------------------------------------------------</td>
</tr>
<tr>
<td><strong>Primary cutaneous gamma delta T-cell lymphoma</strong></td>
<td>- Important to exclude other cutaneous T-cell lymphomas/lymphoproliferative disorders that may also be derived</td>
</tr>
<tr>
<td>Lymphoma Type</td>
<td>Description</td>
</tr>
<tr>
<td>--------------------------------------------------------</td>
<td>-------------------------------------------------------------------------------------------------------</td>
</tr>
<tr>
<td>Primary cutaneous acral CD8+ T-cell lymphoma</td>
<td>New indolent provisional entity, originally described as originating in the ear</td>
</tr>
<tr>
<td>Primary cutaneous CD4+ small medium T-cell lymphoma</td>
<td>No longer to be diagnosed as an overt lymphoma due to limited clinical risk, localized disease, and similarity to clonal drug reactions. Remains a provisional entity.</td>
</tr>
<tr>
<td>Peripheral T-cell lymphoma (PTCL), NOS</td>
<td>Subsets based on phenotype and molecular abnormalities being recognized that may have clinical implications but are mostly not a part of routine practice at this time.</td>
</tr>
<tr>
<td>Nodal T-cell lymphomas with TFH phenotype</td>
<td>An umbrella category created to highlight the spectrum of nodal lymphomas with a TFH phenotype including angioimmunoblastic T-cell lymphoma, follicular T-cell lymphoma and other nodal PTCL with a TFH phenotype (specific diagnoses to be used due to clinicopathologic differences). Overlapping recurrent molecular/cytogenetic abnormalities recognized that potentially could impact therapy.</td>
</tr>
<tr>
<td>ALK-negative anaplastic large cell lymphoma</td>
<td>Now a definite entity that includes cytogenetic subsets that appear to have prognostic implications (eg, 6p25 rearrangements at IRF4/DUSP22 locus).</td>
</tr>
<tr>
<td>Breast implant-associated anaplastic large cell lymphoma</td>
<td>New provisional entity distinguished from other ALK-ALCL; non-invasive disease associated with excellent outcome.</td>
</tr>
<tr>
<td>Nodular lymphocyte predominant Hodgkin lymphoma</td>
<td>Variant growth patterns, if present, should be noted in diagnostic report, due to their clinicopathologic associations. Cases associated with synchronous or subsequent sites that are</td>
</tr>
</tbody>
</table>
indistinguishable from T-cell histioyte rich large B-cell lymphoma (THRLBCL) without a nodular component should be designated THRLBCL-like transformation.

| Lymphocyte rich classical Hodgkin lymphoma | - Features recognized that are intermediate between NLPHL and other types of classical Hodgkin lymphoma. |
| Erdheim-Chester disease | - Should be distinguished from other members of the juvenile xanthogranuloma family; often associated with BRAF mutations. |
| Other histiocytic/dendritic neoplasms | - Clonal relationship to lymphoid neoplasms recognized in some cases. |
Figure legends

Figure 1. New provisional B-cell lymphoma entities. **Large B-cell lymphoma with IRF4 rearrangement** (A) Note the very large abnormal-appearing follicles in the central portion of this tonsil. (B) The neoplastic follicles have numerous transformed cells that are (C) IRF4/MUM-1 and (D) BCL6 positive. **Burkitt-like lymphoma with 11q aberration** (E) The touch imprint demonstrates a monotonous population of transformed cells with basophilic cytoplasm that are (F) CD20 positive, (G) have a very high MIB1/Ki-67 proliferation fraction and are (H) BCL6 positive.

Figure 2. Proposed model of molecular pathogenesis in the development and progression of major subtypes of mantle cell lymphoma (modified from Jares, et al\(^30\) and Swerdlow, et al (WHO Classification of Tumours of Haematopoietic and Lymphoid Tissues. World Health Organization Classification of Tumours. Lyon, IARC, 2016 revision in press). Precursor B-cells usually with but sometimes without a **CCND1** rearrangement mature to abnormal naïve B-cells which may initially colonize, often the inner portion of the mantle zones, representing in situ mantle cell neoplasia. These cells already have additional molecular genetic abnormalities, such as inactivating **ATM** mutations. They may progress to classical MCL which most frequently is SOX11+, has no evidence of transit through the germinal center and is genetically unstable acquiring additional abnormalities related to cell cycle dysregulation, the DNA damage response pathway, cell survival and other pathways. Ultimately progression to blastoid or pleomorphic MCL may occur. A smaller proportion of neoplastic mantle cells may undergo somatic hypermutation, presumably in germinal centers, leading to SOX11- MCL that are more genetically stable for long periods of time and which preferentially involve the PB, BM and
sometimes the spleen. Even these MCL, however, may undergo additional molecular/cytogenetic abnormalities, particularly TP53 abnormalities, leading to clinical and sometime morphological progression. Professional illustration by Patrick Lane, ScEYEnce Studios.

Figure 3. **NOTCH1 mutation detected by NGS and Sanger sequencing.** A. **NOTCH1** p.P2514fs*4 (NP_060087.3) (c.7541-7542delCT, NM_017617.3) mutation detected by NGS (MiSeq, Illumina) as visualized in the Integrative Genomics Viewer (IGV, www.broadinstitute.org/igv, human reference genome GRCh37/hg19) (left, mutated case) and the same region of a **NOTCH1** unmutated sample (right, unmutated case). In each case, the nucleotide coverage as well as few representative NGS reads are shown. A deletion of AG (CT if considering the reverse strand) is observed in the mutated case. By NGS, each read is represented by a gray horizontal bar and the deletion is represented as a black line within those reads carrying the mutation. A decrease in 50% of the coverage can be observed for the two nucleotides effected showing that the mutation is present in half of the reads; B. Sanger sequencing results are shown under the reference nucleotide and amino acid sequences.

Figure 4. **Diagnostic approach to high grade B-cell lymphomas.** (modified from Kluin, P et al, High Grade B-cell Lymphoma, in Swerdlow, SH, et al **WHO Classification of Tumours of Haematopoietic and Lymphoid Tissues,** World Health Organization Classification of Tumours. Lyon, IARC, 2016 revision, in press) Lymphomas that potentially fall into the HGBL categories can morphologically resemble B-lymphoblastic (B-Lbic), Burkitt (BL), and diffuse large B-cell lymphomas (DLBCL) as well as lymphomas that are intermediate between DLBCL and BL (DLBCL/BL). These distinctions can be very subjective. The orange arrows indicate cases with a
BL phenotype and a MYC rearrangement without BCL2 or BCL6 rearrangements (‘single hit’). The red arrows indicate cases with MYC and BCL2 and/or BCL6 rearrangements (‘double or triple hit’). Neither mantle cell lymphomas, subtypes of large B-cell lymphomas, nor Burkitt-like lymphoma with 11q aberration are indicated in this diagram. Professional illustration by Patrick Lane, ScEYEnce Studios.

Figure 5. Cytologic spectrum of high grade B-cell lymphoma, with MYC and BCL2 and/or BCL6 rearrangements. (A, B) This HGBL with MYC and BCL6 rearrangements closely resembles a Burkitt lymphoma including a starry sky with tingible body macrophages and many intermediate-sized transformed cells although there are some subtle cytologic differences from a classic Burkitt lymphoma. (C) This HGBL with MYC, BCL2 and BCL6 rearrangements appears more blastoid but was TdT negative. (D) This HGBL with MYC and BCL2 rearrangements would otherwise have been considered a diffuse large B-cell lymphoma that included many immunoblastic-type cells with single prominent central nucleoli.

Figure 6. T-cell lymphomas. ALK negative anaplastic large cell lymphoma with DUSP22 rearrangement (A) There is a relatively monotonous proliferation of large transformed cells and classic “Hallmark” cells. Breast implant-associated anaplastic large cell lymphoma (B) The seroma cavity demonstrates numerous very large anaplastic-appearing lymphoid cells (Romanovsky type stain). Primary cutaneous acral CD8+ T-cell lymphoma (C) Nodule on the ear. (D) There is a diffuse monotonous infiltrate of CD8+ T-cells (CD8 immunostain). Enteropathy-associated T-cell lymphoma (E) The somewhat pleomorphic intestinal infiltrate extends into the epithelium and would be associated with enteropathic changes elsewhere in the intestine. Monomorphic epitheliotropic intestinal T-cell lymphoma (F) The monotonous intestinal infiltrate is very epitheliotropic. Primary cutaneous CD4 positive small/medium T-cell
lymphoproliferative disorder (G) Small nodule on scalp. (H) Although the infiltrate is dense and lymphoma-like, this is now to be considered a lymphoproliferative disorder rather than a “lymphoma”.
Figure 3

A

NOTCH1 p.P2514fs*4 mutated case

NOTCH1 unmutated case

B

Figure 3
Figure 4

Morphology

Blastoid

Phenotype & cytogenetics

TdT+  TdT-, cyclin D1-

Diagnosis

B-LBic  HGBL, NOS  BL  HGBL, with MYC and BCL2 and/or BCL6R  DLBCL, NOS
The 2016 revision of the World Health Organization (WHO) classification of lymphoid neoplasms

Steven H. Swerdlow, Elias Campo, Stefano A. Pileri, Nancy Lee Harris, Harald Stein, Reiner Siebert, Ranjana Advani, Michele Ghielmini, Gilles A. Salles, Andrew D. Zelenetz and Elaine S. Jaffe